HC Wainwright Has Negative Forecast for ACAD Q2 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a report issued on Thursday, May 8th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will earn $0.11 per share for the quarter, down from their prior forecast of $0.16. HC Wainwright currently has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals' Q3 2025 earnings at $0.17 EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at $0.61 EPS, FY2026 earnings at $1.86 EPS and FY2029 earnings at $2.33 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.10 by $0.01. The company had revenue of $244.32 million during the quarter, compared to analyst estimates of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The business's revenue was up 18.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 earnings per share.

ACAD has been the topic of several other research reports. StockNews.com cut shares of ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday. Morgan Stanley reaffirmed an "equal weight" rating and issued a $20.00 price target on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Deutsche Bank Aktiengesellschaft started coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a "hold" rating and a $22.00 target price on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 8th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $24.70.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ ACAD traded down $0.04 during mid-day trading on Friday, reaching $17.16. 1,841,359 shares of the company traded hands, compared to its average volume of 1,857,324. ACADIA Pharmaceuticals has a fifty-two week low of $13.40 and a fifty-two week high of $20.68. The firm has a market cap of $2.87 billion, a PE ratio of 22.00 and a beta of 0.47. The stock has a fifty day simple moving average of $15.81 and a 200-day simple moving average of $17.00.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. bought a new position in ACADIA Pharmaceuticals in the 1st quarter worth approximately $60,845,000. Point72 Asset Management L.P. acquired a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth approximately $40,935,000. SG Americas Securities LLC raised its position in ACADIA Pharmaceuticals by 380.3% in the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after purchasing an additional 1,966,607 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of ACADIA Pharmaceuticals by 1,055.8% in the first quarter. American Century Companies Inc. now owns 1,632,749 shares of the biopharmaceutical company's stock valued at $27,120,000 after buying an additional 1,491,484 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth $25,555,000. Institutional investors own 96.71% of the company's stock.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,171 shares of ACADIA Pharmaceuticals stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $54,065.55. Following the completion of the sale, the executive vice president now owns 56,889 shares of the company's stock, valued at $969,957.45. This trade represents a 5.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the transaction, the director now directly owns 17,595 shares in the company, valued at $320,756.85. This trade represents a 21.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,994 shares of company stock worth $313,131. 26.50% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.